Safety and Efficacy Study of Switching From Epzicom to Truvada
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate
the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed
dose emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in virologically suppressed,
human immunodeficiency virus type 1 (HIV-1) infected subjects maintained on a
ritonavir-boosted protease inhibitor (PI/r)-containing antiretroviral (ARV) regimen. Duration
of treatment is 48 weeks.